TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01373021
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 2500mcg+NS50ml
Study: NCT02723539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02027155
Drug: AR09 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: moderate levels of sedation
Study: NCT02027155
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Saline, USP
Study: NCT02030808
Drug: Muscle Relaxants (MR) group
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
Study: NCT02030808
Drug: Non- Muscle Relaxants (NMR) group
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cisatracurium® (Nimbex) will be administered
Study: NCT03710772
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03710772
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03710772
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03406377
Drug: OPK-88003
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPK-88003 subcutaneous injection
Study: NCT03406377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT00852683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg twice a day
Study: NCT01704079
Drug: CTAP101 30 μg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTAP101 30 μg capsule taken daily at bedtime
Study: NCT03587116
Drug: Standard of Care FIX Replacement therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
Study: NCT03587116
Drug: Standard of Care FVIII Replacement therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Study: NCT01703910
Drug: arm B chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00394095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo to Experimental arm
Study: NCT02849418
Drug: GSK1358820
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
Study: NCT02849418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection contains sodium chloride (0.9 milligrams \[mg\]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
Study: NCT01517399
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 200 mg oral tablet once alone and once again with tivantinib
Study: NCT03380806
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard LHRH agonist for 3 years
Study: NCT03995641
Drug: marcaine and kenalog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
Study: NCT00144807
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00144807
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02662309
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01954992
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
Study: NCT04176783
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: narcotic pain medicine
Study: NCT04176783
Drug: Opioid-Free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: non narcotoc pain medication
Study: NCT01523171
Drug: SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT03379168
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone is a standard of care injection to reduce joint inflammation.
Study: NCT02040376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
Study: NCT00992108
Drug: chemodenervation
Approvals — FDA: no, EMA: no, PMDA: no
Description: botulinum toxin
Study: NCT04497012
Drug: 2mg/kg/day Iron Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
Study: NCT04497012
Drug: 6 mg/kg/day Iron Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
Study: NCT00607776
Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drops
Study: NCT04106557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules to OV101 capsules.
Study: NCT03175367
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC or IV administration
Study: NCT03123692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days treatment with placebo
Study: NCT01533207
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02561884
Drug: Olostar Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02561884
Drug: Co-administration of Olmetec and Crestor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03320707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
Study: NCT03671681
Drug: Prophylactic
Normalized name: Caries prophylactic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
Study: NCT03484702
Drug: JCAR017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01918527
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally on days 1-14: 2000 mg/m2/day q3w
Study: NCT00331201
Drug: SAFEstart
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00381810
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01803438
Drug: Antiarrhythmic Drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
Study: NCT04457297
Drug: trifluridine and tipiracil
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
Study: NCT04457297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
Study: NCT04445285
Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
Study: NCT03331315
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03331315
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00213044
Drug: Carraguard (PC-515)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02675465
Drug: ATB200
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02309346
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
Study: NCT03774732
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
Study: NCT04418024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active control
Study: NCT03169777
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03169777
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03169777
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT03279081
Drug: Cx601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cx601 eASCs intralesional injection.
Study: NCT00611936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04160117
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Study: NCT01365923
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil effect site-TCI 2-4ng/ml
Study: NCT01365923
Drug: dexmedetomidine with remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
Study: NCT00274586
Drug: Aggrenox® modified release capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00274586
Drug: Aggrenox® modified release capsules matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03107988
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
Study: NCT00352768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01052493
Drug: PP 1420
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
Study: NCT01052493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT02135250
Drug: Xinkeshu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Xinkeshu tablets are given three times per day
Study: NCT01521117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
Study: NCT03923166
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 500mg tid
Study: NCT01105429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 0mg, once daily, 1 day
Study: NCT01105429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, (TBD), once daily, 2 days
Study: NCT00771758
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
Study: NCT05056935
Drug: LB1148
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
Study: NCT05056935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Study: NCT03931291
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
Study: NCT04377126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of saline- no active ingredient.
Study: NCT02005458
Drug: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02005458
Drug: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02005458
Drug: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03420963
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04333576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet:Oral
Study: NCT04707248
Drug: DS-6000a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
Study: NCT04707248
Drug: DS-6000a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration at RDE on Day 1 of Cycle 1
Study: NCT04747964
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
Study: NCT04747964
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
Study: NCT04747964
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
Study: NCT04747964
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
Study: NCT04747964
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
Study: NCT04747964
Drug: STSP-0601 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
Study: NCT03598842
Drug: Anti-parasitic medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
Study: NCT03215069
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO daily
Study: NCT00739648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same frequency as study drug using the same method of delivery
Study: NCT02662374
Drug: .02% Chlorohexidine Gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml of the drug in mouthwash form to be swished four times a day
Study: NCT04009343
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
Study: NCT04402489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02157532
Drug: Best standard treatment
Normalized name: Best Choice Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous r-tPA infusion or any other medical management option
Study: NCT01099670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01085149
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg simvastatin, slow release in socket of extracted tooth (single application only)
Study: NCT03755037
Drug: Clomid, Respatio and Ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs were received during the menstrual cycle.
Study: NCT02991807
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.
Study: NCT02991807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.
Study: NCT01868269
Drug: dexamethasone and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
Study: NCT03117192
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc supplementation in syrup form
Study: NCT02839291
Drug: intravenous or oral bone antiresorptive treatments
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03323463
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
Study: NCT04448808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of BX-1, oral solution
Study: NCT03479476
Drug: Placebo Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid or capsules given in parallel to active medication.
Study: NCT02443077
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04467905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
Study: NCT02702492
Drug: KPT-9274
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04088890
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500 mg/m2
Study: NCT01002573
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen, 10 mg/kg
Study: NCT01002573
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 10mg/kg
Study: NCT00698763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are identical in appearance to active capsules
Study: NCT01031212
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously over 20 minutes weekly after chemotherapy
Study: NCT03414502
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.